Teleflex Acquires Essential Medical

Acquisition expands presence in structural heart and endovascular
aneurysm repair markets by adding unique large bore closure system

WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX) today announced that it has acquired
Essential Medical, Inc. Based in Exton, PA, Essential Medical is a
privately-held medical device company that has developed and
commercialized the CE Marked MANTA™ Vascular Closure Device specifically
designed for closure of large bore arteriotomies following procedures
utilizing devices or sheaths ranging in size from 10F to 18F (with
maximum outer diameters up to 25F). In its CE Mark study, the MANTA
Device demonstrated rapid and reliable hemostasis with its resorbable
collagen-based technology and complication rates that were non-inferior
to surgical and suture-based closure methods.(1)

“We are very excited to announce this acquisition, which expands our
presence in the structural heart and endovascular aneurysm repair
markets,” said Liam Kelly, President and Chief Executive Officer of
Teleflex. Added Mr. Kelly, “The MANTA Vascular Closure Device represents
a truly innovative solution to address closure-related complications and
high costs associated with many large and rapidly growing interventional
procedure categories, such as transcatheter aortic valve replacement,
endovascular aneurysm repair and ventricular assist device implantation.
Physician adoption of the MANTA Device in international markets has been
impressive, with over 8,100 procedures completed to date across a number
of countries in the EU. We believe we can leverage our strong presence
in the interventional cardiology market to accelerate adoption and
growth of this breakthrough technology worldwide. Following the
anticipated FDA premarket approval of the MANTA Device in 2019, we
expect the acquisition will be modestly accretive to our constant
currency revenue growth and gross margins over a multi-year period.”

“The combination of Teleflex and Essential Medical provides an excellent
opportunity to maximize physician and patient access to the MANTA™
Vascular Closure Device,” stated Greg Walters, Essential Medical’s
co-founder, President and CEO. “We are delighted to become an important
part of Teleflex’s interventional cardiology business.”

The MANTA Device is not approved for sale or distribution in the United


Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rusch®,
UroLift® and Weck® – trusted brands united by a
common sense of purpose.


Essential Medical is a privately held medical device company aiming to
develop and commercialize new vascular closure devices for femoral
punctures following diagnostic and interventional cardiac
catheterization procedures. The company was founded in 2010 by Greg
Walters, a senior product development executive with 23 years of
experience creating innovative cardiovascular products, and Dr. Gary
Roubin, MD, PhD, a coronary and carotid stenting pioneer.

(1) “Percutaneous Plug-Based Arteriotomy Closure Device for
Large-Bore Access” by Nicolas M. Van Mieghem, MD, et al in Journal of
the American College of Cardiology: Cardiovascular Interventions, Vol
10, No. 6, 2017.


This press release contains forward-looking statements, including, but
not limited to, statements related to expected benefits to Teleflex from
the acquisition, including incremental constant currency revenue growth
and anticipated gross margin expansion; and expectations regarding our
ability to leverage our presence in the interventional cardiology
market. Actual results could differ materially from those in the
forward-looking statements due to, among other things, unanticipated
delays or difficulties in obtaining FDA premarket approval of the MANTA
Device; changes in business relationships with and purchases by or from
major customers or suppliers; delays or cancellations in shipments;
demand for and market acceptance of new and existing products; our
inability to integrate acquired businesses into our operations, realize
planned synergies and operate such businesses profitably in accordance
with our expectations; the inability of acquired businesses to generate
revenues in accordance with our expectations; the impact of healthcare
reform legislation and proposals to amend the legislation; changes in
Medicare, Medicaid and third party coverage and reimbursements;
competitive market conditions and resulting effects on revenues and
pricing; increases in raw material costs that cannot be recovered in
product pricing; global economic factors difficulties in entering new
markets; general economic conditions; and other factors described or
incorporated in our filings with the Securities and Exchange Commission
(“SEC”), including our Annual Report on Form 10-K for the year ended
December 31, 2017.


Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President of Investor Relations


I have been involved with publishing and marketing for the past 32 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.com for scheduling information.